Search
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
PF-04995274
go.drugbank.com/drugs/DB12675InvestigationalPf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274
2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid
go.drugbank.com/drugs/DB19221Investigational2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid is under investigation in clinical trial NCT03774394 (Impact of Chronic Kidney Disease on Clopidogrel Effects in
IMM-0306
go.drugbank.com/drugs/DB19309Investigational0306 (bispecific antibody-trap selectively targeting cd47 and cd20) is under investigation in clinical trial NCT05805943 (Study of IMM0306 in Patients With Relapsed or Refractory Cd20-positive B-cell Non-hodgkin's
Libivirumab
go.drugbank.com/drugs/DB17748ExperimentalIt is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
Apocynin
go.drugbank.com/drugs/DB12618InvestigationalAcetovanillone has been used in trials studying the treatment of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.
Categories: Analgesics, Non-NarcoticPegcrisantaspase
go.drugbank.com/drugs/DB16281InvestigationalFollowing Hypersensitivity to Pegaspargase (Oncaspar)).
Pinatuzumab vedotin
go.drugbank.com/drugs/DB15432InvestigationalNCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's